References
- Zanchetti A. Trough and peak effects of a single daily dose of nifedipine gastrointestinal therapeutic system (GITS) as assessed by ambulatory blood pressure monitoring. J Hypertens 1994; 12(Suppl 5)S23–S27
- Bailey D. G., Arnold J. M. O., Bend J. R., et al. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol 1995; 40: 135–140
- Leenen F. H. H., Fourney A. Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure plasma catecholamines and left ventricular mass. AmJCardiol 1996; 78: 203–207
- Leenen F. H. H., Fourney A., Notman C., Tanner J. Persistence of antihypertensive effect after ‘missed doses’ of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996; 41: 83–88
- Huang B. S., Leenen F. H. H. Sympatho-inhibitory effects of central nifedipine in SHR on high versus regular sodium intake. Hypertension, (in press)
- Leenen F. H. H., Holliwell D. L. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992; 69: 639–645
- Grossman E., Messerli F. H. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997; 80: 1453–1458
- Leenen F. H. H. Dihydropyridine calcium antagonists and sympathetic activity: relevance to cardiovascular morbidity and mortality. Calcium Antagonists in Clinical Medicine2nd edition., M. Epstein, 1998; 527–551
- Hamada T., Watanabe M., Kaneda T., Ohtahara A., et al. Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J Hypertens 1998; 16: 111–118
- de Champlain J., Karas M., Nguygen P., et al. Different effects of nifedipine and amlodipine on circulating catecholamines levels in essential hypertensive patients. J Hypertens 1998; 16: 1357–1369
- Stone P. H., Muller J. E., Turi Z.G., et al. Efficacy of nifedipine therapy in patients with refractory angina pectoris: significance of the presence of coronary vasospasm. Am Heart J 1983; 106: 644–652
- Thadani U., Zellner S. R., Glasser S., et al. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine: a new second-generation calcium channel blocker in angina pectoris. Circulation 1991; 84: 2398–2408
- Glasser S., Clark P., Lipicky R., Hubbard J., Yusuf S. Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials. J Am Med Assoc 1991; 265: 1550–1554
- Lichtlen P. R., Hugenholtz P. G., Rafflenbeul W., et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990; 335: 1109–1113
- Waters D., Lesperance J., Francetich M., et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82: 1940–1953
- Yusuf S., Held P. H., Furberg C. D. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67: 1295–1297
- Cruickshank J. M., Lewis J., Moore V., Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992; 6: 85–90
- Borhani N. O., Mercuri M., Borhani P. A., et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785–791
- Jennings G. L., Wong J. Reversibility of left ventricular hypertrophy and malfunction by antihypertensive treatment. Handbook for Hypertension: Assessment of Hypertensive Organ Damage. L Hansson and W. H. Birkenhager 1997; 184–223
- Proschan M., Davis B., Cutler J., et al. ALLHAT and calcium channel blockers. Am J Hypertens 1997; 10: 142–143